Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00103597|
Recruitment Status : Completed
First Posted : February 14, 2005
Last Update Posted : October 20, 2005
|Condition or disease||Intervention/treatment||Phase|
|Parkinson's Disease Multiple System Atrophy Orthostatic Hypotension||Drug: Fludrocortisone Drug: Domperidone Behavioral: Conservative Measures for Orthostatic Hypotension||Phase 1|
Enrolled patients, ages 40-95, must have Parkinson's or MSA, diagnosed by a neurologist, and symptoms of orthostatic hypotension. Each patient will fill out two validated questionnaires to determine if they are candidates for the study. Baseline patient details, such as their medications and UPDRS, will be recorded. Medications must be held stable during the period of the study.
Each patient will then have three weeks of conservative therapy, three weeks of therapy with fludrocortisone, and three weeks of therapy with domperidone. Autonomic testing, a symptom questionnaire, bedside blood pressure testing, and UPDRS will be performed after each intervention.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||50 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy|
|Study Start Date :||January 2005|
|Study Completion Date :||September 2005|
U.S. FDA Resources
- Efficacy of conservative treatment, domperidone, and fludrocortisone for patient's subjective symptoms of orthostatic hypotension, and on objective autonomic testing
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00103597
|Royal Brisbane and Women's Hospital|
|Brisbane, Queensland, Australia, 4029|
|Principal Investigator:||Kerrie Schoffer, MBBS||Movement Disorders Fellow|